Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Esperion Therapeutics Inc (NASDAQ: ESPR) closed at $3.7 in the last session, up 0.27% from day before closing price of $3.69. In other words, the price has increased by $0.27 from its previous closing price. On the day, 2.83 million shares were traded. ESPR stock price reached its highest trading level at $3.77 during the session, while it also had its lowest trading level at $3.66.
Ratios:
We take a closer look at ESPR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.15.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on November 25, 2025, initiated with a Overweight rating and assigned the stock a target price of $9.
On December 18, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.Cantor Fitzgerald initiated its Overweight rating on December 17, 2024, with a $8 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 17 ’25 when Koenig Sheldon L. sold 48,244 shares for $3.67 per share. The transaction valued at 177,200 led to the insider holds 1,470,587 shares of the business.
Halladay Benjamin sold 7,337 shares of ESPR for $26,905 on Dec 17 ’25. The Chief Financial Officer now owns 467,525 shares after completing the transaction at $3.67 per share. On Dec 17 ’25, another insider, Looker Benjamin, who serves as the General Counsel of the company, sold 6,517 shares for $3.67 each. As a result, the insider received 23,898 and left with 385,905 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 877156160 and an Enterprise Value of 1385694208. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.91. Its current Enterprise Value per Revenue stands at 4.561 whereas that against EBITDA is -47.335.
Stock Price History:
The Beta on a monthly basis for ESPR is 1.04, which has changed by 0.6894977 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $4.13, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 10.26%, while the 200-Day Moving Average is calculated to be 81.01%.
Shares Statistics:
According to the various share statistics, ESPR traded on average about 6.76M shares per day over the past 3-months and 4848170 shares per day over the past 10 days. A total of 239.06M shares are outstanding, with a floating share count of 235.40M. Insiders hold about 1.53% of the company’s shares, while institutions hold 53.00% stake in the company. Shares short for ESPR as of 1765756800 were 28827852 with a Short Ratio of 4.27, compared to 1763078400 on 24958080. Therefore, it implies a Short% of Shares Outstanding of 28827852 and a Short% of Float of 12.21.
Earnings Estimates
A detailed examination of Esperion Therapeutics Inc (ESPR) is currently in progress, with 7.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.07 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.23 and -$0.42 for the fiscal current year, implying an average EPS of -$0.07. EPS for the following year is $0.03, with 7.0 analysts recommending between $0.4 and -$0.32.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $164.7M. It ranges from a high estimate of $211.4M to a low estimate of $97.33M. As of. The current estimate, Esperion Therapeutics Inc’s year-ago sales were $69.11MFor the next quarter, 8 analysts are estimating revenue of $109.49M. There is a high estimate of $155.84M for the next quarter, whereas the lowest estimate is $88.1M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $446.1M, while the lowest revenue estimate was $283.93M, resulting in an average revenue estimate of $393.11M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $379.59M in the next fiscal year. The high estimate is $433.01M and the low estimate is $339.03M.
